Study Details
Design, interventions, and primary outcomes
About This Study
This clinical research aims to determine if concurrent chemotherapy and radiation therapy is more effective than sequential chemotherapy and radiation therapy for patients with stage IIB-III breast cancer. It seeks to answer the following key questions: 1. When compared to sequential treatment, does concurrent chemoradiotherapy increase disease-free survival? 2. What effects does concurrent treatment have on post-operative look, quality of life, and side effects including arm swelling (lymphoedema)? 3. What are each treatment approach's financial costs? Researchers will compare the following to groups: Arm A: Participants in the sequential treatment group will first undergo chemotherapy and then radiation. and Arm B: Participants in the concurrent treatment group will undergo radiation therapy while undergoing chemotherapy. Participants are going to: 1. Get the usual chemotherapy (taxanes and/or anthracyclines). 2. Receive radiation therapy for three to four weeks. 3. Have follow-up visits every 6months for 5years to check for cancer recurrence, side effects, and quality of life.
Design
Interventions / Regimen
- Drug: Chemoradiation — This intervention will consist of getting chemotherapy followed by radiotherapy, i.e, in a sequential manner
- Drug: Chemoradiation — This intervention will consist of getting chemotherapy and radiotherapy at the same time, i.e, in a concurrent manner.
Primary Outcomes
- Study the 3-year Disease Free Survival. (From enrollment to 3 years after treatment at six months intervals.)
Phase: PHASE3
Status: Recruiting
Start Date: 2024-05-14
Completion: 2031-05
Sex: ALL
Volunteers: false
Enrollment: 858 (ESTIMATED)
- Drug: Chemoradiation — This intervention will consist of getting chemotherapy followed by radiotherapy, i.e, in a sequential manner
- Drug: Chemoradiation — This intervention will consist of getting chemotherapy and radiotherapy at the same time, i.e, in a concurrent manner.